Could a shock drug help ARDS patients breathe easier? new trial launches
NCT ID NCT05241067
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether centhaquine, a drug already approved for shock, can help people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. About 80 ICU patients will receive centhaquine or a placebo alongside standard care. The goal is to see if the drug improves oxygen levels and reduces deaths.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.